SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of June 2007
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
 |
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Commences Patient Enrolment in
U.S. Phase II Sarcoma Clinical Trial
CALGARY, AB, — June 27, 2007 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY)
announced today that patient enrolment has commenced in its U.S. Phase II trial to evaluate the
intravenous administration of REOLYSIN® in patients with various sarcomas that have
metastasized to the lung. Patients are being enrolled at the Montefiore Medical Center/Albert
Einstein College of Medicine in the Bronx, New York, the University of Michigan Comprehensive
Cancer Center in Ann Arbor, and the Cancer Therapy and Research Center, Institute for Drug
Development in San Antonio, Texas.
“The initiation of this trial represents an important milestone for the Company,” said Dr.
Brad Thompson, President and CEO of Oncolytics. “We are now treating patients with advanced
cancers in Phase II clinical trials in the U.S. and the U.K., with additional Phase II trials
expected to begin before the end of the year. These trials are expected to yield information that
will guide the late stage clinical development program for REOLYSIN®.”
The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to
measure tumour responses and duration of response, and to describe any evidence of antitumour
activity of intravenous, multiple dose REOLYSIN® in patients with bone and soft tissue
sarcomas metastatic to the lung. REOLYSIN® will be given intravenously to patients at a
dose of 3x1010 TCID50 for five consecutive days. Patients may receive
additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52
patients will be enrolled in the study.
Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their
physician to be unresponsive to or untreatable by standard therapies. These include patients with
osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma,
fibrosarcoma and leiomyosarcoma.
“There are very few treatment options for patients with bone or soft tissue sarcomas,” said Dr.
Matt Coffey, Oncolytics’ Chief Scientific Officer. “Our decision to choose this indication is
based on the observed activity of REOLYSIN® against sarcomas in both preclinical and
clinical studies.”
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I and
Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company’s expectations related to the U.S. Phase II sarcoma clinical trial and the Company’s belief
as to the potential of REOLYSIN® as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company’s actual results to differ materially from
those in the forward-looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the tolerability of REOLYSIN® outside a
controlled test, the success and timely completion of clinical studies and trials, the Company’s
ability to successfully commercialize REOLYSIN®, uncertainties related to the research
and development of pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements.
The Company does not undertake to update these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
Oncolytics Biotech Inc.
|
|
The Equicom Group
|
|
The Investor Relations Group |
Cathy Ward
|
|
Nick Hurst
|
|
Erika Moran |
210, 1167 Kensington Cr NW
|
|
325, 300 5th Ave. SW
|
|
11 Stone St, 3rd Floor |
Calgary, Alberta T2N 1X7
|
|
Calgary, AB, T2P 3C4
|
|
New York, NY 10004 |
Tel: 403.670.7377
|
|
Tel: 403.538.4845
|
|
Tel: 212.825.3210 |
Fax: 403.283.0858
|
|
Fax: 403.237.6916
|
|
Fax: 212.825.3229 |
cathy.ward@oncolytics.ca
|
|
nhurst@equicomgroup.com
|
|
emoran@investorrelationsgroup.com |
-30-